A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

tive example of the use of a measurement in a clinical trial (in some instances for regulatory approval). The task force met initially in person for discussion. The results were summarized in a draft manuscript by the primary authors (G.D. and W.J.S.) and discussed at the annual IOIBD meetings in 2004 and 2005. The manuscript was then circulated to the entire IOIBD membership; the leadership of the European Crohn’s and Colitis Organization (ECCO); the leadership of 3 groups of investigators who conduct clinical trials in inflammatory bowel disease (IBD) in the United States (the clinical alliance of the Crohn’s and Colitis Foundation of America), Canada (the clinical network of the Crohn’s and Colitis Founda

[1]  Sanjay Kaul,et al.  Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials , 2006, Annals of Internal Medicine.

[2]  S. Targan,et al.  Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial , 2006, Gut.

[3]  G. Radford-Smith,et al.  Comparison of the efficacy and safety of Eudragit‐L‐coated mesalazine tablets with ethylcellulose‐coated mesalazine tablets in patients with mild to moderately active ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[4]  W. Sandborn,et al.  Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[6]  F. Ajayi,et al.  Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial , 2005, The American Journal of Gastroenterology.

[7]  P. Rutgeerts,et al.  Infliximab Results in Reduction of Inflammation and Inflammatory Markers in the Mucosa of Ulcerative Colitis Patients: The ACT 1 Trial , 2005 .

[8]  M. Kamm,et al.  Comparison of the Efficacy and Safety of SPD476, a Novel, Once-Daily, High-Dose Formulation of Mesalamine, and Asacol with Placebo for the Induction of Remission of Mild-Moderate Ulcerative Colitis: A Phase III Study , 2005 .

[9]  G. Porro,et al.  A rare cause of diuretic refractory ascites , 2005, Gut.

[10]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[11]  P. Marteau,et al.  An unusual cause of soft tissue infection , 2005, Gut.

[12]  R. Modigliani,et al.  A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. , 2005, Gastroenterology.

[13]  M. Spehlmann,et al.  Interferon-β-1a for the Treatment of Steroid-Refractory Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial , 2005 .

[14]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[15]  M. Schwartz,et al.  Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis , 2005, Gut.

[16]  M. Schwartz,et al.  Is Endoscopy Necessary for the Measurement of Disease Activity in Ulcerative Colitis? , 2005, The American Journal of Gastroenterology.

[17]  B. Göke,et al.  Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study , 2004, European journal of gastroenterology & hepatology.

[18]  M. Stolte,et al.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine , 2004, Gut.

[19]  S. V. van Deventer,et al.  A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis , 2004, Gut.

[20]  G. Greenberg,et al.  Comparison of a Disease Activity Index and Patients’ Self-Reported Symptom Severity in Ulcerative Colitis , 2004, Inflammatory bowel diseases.

[21]  J. Goldblum,et al.  Patterns of colonic involvement at initial presentation in ulcerative colitis: a retrospective study of 46 newly diagnosed cases. , 2004, American journal of clinical pathology.

[22]  K. Petraki,et al.  A Prospective Randomized Observer-Blind 2-Year Trial of Azathioprine Monotherapy versus Azathioprine and Olsalazine for the Maintenance of Remission of Steroid-Dependent Ulcerative Colitis , 2004, American Journal of Gastroenterology.

[23]  G. Tomlinson,et al.  Are claims of equivalency in digestive diseases trials supported by the evidence? , 2004, Gastroenterology.

[24]  P. Bello,et al.  International Study Group , 2004 .

[25]  H. Tilg,et al.  A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis , 2003 .

[26]  P. Rutgeerts,et al.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. , 2003, Gastroenterology.

[27]  R. Playford,et al.  Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. , 2003, The New England journal of medicine.

[28]  B. Sands,et al.  Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial , 2003, Alimentary pharmacology & therapeutics.

[29]  D. Levine,et al.  A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis , 2002, American Journal of Gastroenterology.

[30]  B. Wiens,et al.  Choosing an equivalence limit for noninferiority or equivalence studies. , 2002, Controlled clinical trials.

[31]  M. Stolte,et al.  Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses , 2001, Gut.

[32]  K. Petraki,et al.  A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. , 2001, Scandinavian journal of gastroenterology.

[33]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[34]  L. Mortelmans,et al.  Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. , 2001, Gastroenterology.

[35]  S. Targan,et al.  Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study , 2001, Inflammatory bowel diseases.

[36]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[37]  L. Good,et al.  Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis , 2000, American Journal of Gastroenterology.

[38]  M. Seo,et al.  Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. , 1998 .

[39]  R. Löfberg,et al.  Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis , 1998, European journal of gastroenterology & hepatology.

[40]  S. Hanauer,et al.  Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. , 1998, Gastroenterology.

[41]  C. Kleer,et al.  Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. , 1998, The American journal of surgical pathology.

[42]  R. Pounder,et al.  A simple clinical colitis activity index , 1998, Gut.

[43]  D. Drossman,et al.  Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease , 1998, American Journal of Gastroenterology.

[44]  P. Marteau,et al.  Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study , 1998, Gut.

[45]  Y. Ando.  Transdermal Nicotine for Ulcerative Colitis , 1997, Annals of Internal Medicine.

[46]  R. Hurt,et al.  Transdermal Nicotine for Ulcerative Colitis: Reply , 1997, Annals of Internal Medicine.

[47]  P. Rutgeerts,et al.  Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. , 1997, The American journal of gastroenterology.

[48]  M. Cheang,et al.  Quantification of the placebo response in ulcerative colitis. , 1997, Gastroenterology.

[49]  K. Batts,et al.  Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis , 1997, Annals of Internal Medicine.

[50]  S Gallivan,et al.  Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. , 1997, Journal of clinical pathology.

[51]  B. Feagan,et al.  Does self-administration of a quality of life index for inflammatory bowel disease change the results? , 1996, Journal of clinical epidemiology.

[52]  E. Irvine,et al.  The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. , 1996, The American journal of gastroenterology.

[53]  D. Jewell,et al.  Predicting outcome in severe ulcerative colitis. , 1996, Gut.

[54]  S. Hanauer,et al.  An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis , 1996, Annals of Internal Medicine.

[55]  S. Fredd.  Standards for Approval of New Drugs for IBD. , 1995 .

[56]  R. Modigliani,et al.  Comparison of budesonide and 5‐aminosalicylic acid enemas in active distal ulcerative colitis , 1995, Alimentary pharmacology & therapeutics.

[57]  N. Okabe,et al.  Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts' classification. , 1995, The American journal of gastroenterology.

[58]  C. Bernstein,et al.  Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. , 1995, Gastrointestinal endoscopy.

[59]  D. Drossman,et al.  Psychosocial factors in inflammatory bowel disease. , 1995, Gastroenterology clinics of North America.

[60]  R. Newcombe,et al.  Transdermal nicotine as maintenance therapy for ulcerative colitis. , 1995, The New England journal of medicine.

[61]  S. Hanauer,et al.  Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis , 1995, Digestive Diseases and Sciences.

[62]  A. Nilsson,et al.  Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis , 1994, Alimentary pharmacology & therapeutics.

[63]  H. Goldman.  Interpretation of large intestinal mucosal biopsy specimens. , 1994, Human pathology.

[64]  P. Munkholm,et al.  Course of ulcerative colitis: analysis of changes in disease activity over years. , 1994, Gastroenterology.

[65]  S. Hanauer,et al.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.

[66]  K. Batts,et al.  A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. , 1994, Gastroenterology.

[67]  R G Newcombe,et al.  Transdermal nicotine for active ulcerative colitis. , 1994, The New England journal of medicine.

[68]  J. Rochon,et al.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.

[69]  G H Guyatt,et al.  USERS' GUIDES TO THE MEDICAL LITERATURE. II: HOW TO USE AN ARTICLE ABOUT THERAPY OR PREVENTION A. ARE THE RESULTS OF THE STUDY VALID ? , 1993 .

[70]  E. O'Keefe,et al.  Olsalazine in maintenance of clinical remission in patients with ulcerative colitis , 1993, Digestive diseases and sciences.

[71]  R. Odze,et al.  Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. , 1993, The American journal of surgical pathology.

[72]  S. Hanauer,et al.  Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.

[73]  R. Farmer,et al.  Clinical patterns, natural history, and progression of ulcerative colitis , 1993, Digestive Diseases and Sciences.

[74]  H. Sacks,et al.  Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. , 1993, Journal of clinical gastroenterology.

[75]  P. Munkholm,et al.  Colorectal cancer risk and mortality in patients with ulcerative colitis. , 1992, Gastroenterology.

[76]  D. Drossman,et al.  Ulcerative colitis and Crohn's disease health status scales for research and clinical practice. , 1992, Journal of clinical gastroenterology.

[77]  T. Yao,et al.  An index of disease activity in patients with ulcerative colitis. , 1992, The American journal of gastroenterology.

[78]  A. Axon,et al.  Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. , 1992, BMJ.

[79]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[80]  R. Fedorak,et al.  Quality of Life in Inflammatory Bowel Disease , 1992, Journal of clinical gastroenterology.

[81]  D. Drossman,et al.  Health status and health care use in persons with inflammatory bowel disease , 1991, Digestive Diseases and Sciences.

[82]  S. Kreiner,et al.  Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. , 1991, Scandinavian journal of gastroenterology.

[83]  D. Jewell,et al.  Small bowel gas in severe ulcerative colitis. , 1991, Gut.

[84]  D. Drossman,et al.  The rating form of IBD patient concerns: a new measure of health status. , 1991, Psychosomatic medicine.

[85]  S. Lo,et al.  Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. , 1991, Annals of internal medicine.

[86]  G. Tytgat,et al.  Retrograde Spread of Mesalazine (5-Aminosalicylic Acid)-Containing Enema in Patients with Ulcerative Colitis , 1991, Clinical pharmacokinetics.

[87]  H. Adami,et al.  The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. , 1991, Gastroenterology.

[88]  S. Riley,et al.  Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.

[89]  H. Adami,et al.  Ulcerative colitis and colorectal cancer. A population-based study. , 1990, The New England journal of medicine.

[90]  D. Present,et al.  Preliminary report: cyclosporin in treatment of severe active ulcerative colitis , 1990, The Lancet.

[91]  J. W. Garrett,et al.  Health status in inflammatory bowel disease. Biological and behavioral considerations. , 1990, Gastroenterology.

[92]  M. Appelbaum,et al.  Health-related quality of life in inflammatory bowel disease , 1989, Digestive Diseases and Sciences.

[93]  P. Rutgeerts,et al.  Comparative efficacy of coated, oral 5‐aminosalicylic acid (Claversal * ) and sulphasalazine for maintaining remission of ulcerative colitis , 1989, Alimentary pharmacology & therapeutics.

[94]  G. Guyatt,et al.  A new measure of health status for clinical trials in inflammatory bowel disease. , 1989, Gastroenterology.

[95]  Ami,et al.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.

[96]  P. Blok,et al.  Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. , 1988, Gastroenterology.

[97]  C. H. Mason,et al.  Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. , 1988, Scandinavian journal of gastroenterology. Supplement.

[98]  G. Guyatt,et al.  Quality of life in patients with inflammatory bowel disease. , 1988, Journal of clinical gastroenterology.

[99]  S. Riley,et al.  Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. , 1988, Gastroenterology.

[100]  N. Read,et al.  Symptoms and stool patterns in patients with ulcerative colitis. , 1988, Gut.

[101]  L. Nochomovitz,et al.  Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial. , 1988, Annals of internal medicine.

[102]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[103]  G. Haber,et al.  Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using99mTc-labeled 5-ASA suppositories , 1987, Digestive Diseases and Sciences.

[104]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[105]  R. Willén,et al.  Histologic and colonoscopic assessment of disease extension in ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.

[106]  D. Jewell,et al.  Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. , 1986, Gut.

[107]  J. Lennard-jones,et al.  Controlled trial of bowel rest in the treatment of severe acute colitis. , 1986, Gut.

[108]  C. Smith,et al.  Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. , 1986, Gut.

[109]  A. Axon,et al.  Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. , 1985, Gut.

[110]  G. Järnerot,et al.  Intensive intravenous treatment of ulcerative colitis. , 1985, Gastroenterology.

[111]  F. Deland,et al.  Disposition of radiolabelled suppositories in humans , 1985, The Journal of pharmacy and pharmacology.

[112]  C. Rubio,et al.  A quantitative method of estimating inflammation in the rectal mucosa. IV. Ulcerative colitis in remission. , 1984, Scandinavian journal of gastroenterology.

[113]  J. Goldberg,et al.  Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis: A prospective, randomized, double-blind clinical trial , 1983 .

[114]  D. W. Day,et al.  Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis , 1982, Digestive Diseases and Sciences.

[115]  J. Lennard-jones,et al.  Controlled trial of azathioprine in chronic ulcerative colitis. , 1982, British medical journal.

[116]  A. Axon,et al.  Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. , 1980, Gastroenterology.

[117]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[118]  C. Spicer,et al.  Assessment of severity in colitis: a preliminary study. , 1975, Gut.

[119]  H. Spiro,et al.  A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis. , 1975, Gastroenterology.

[120]  B. Levin,et al.  A controlled trial of azathioprine in the management of chronic ulcerative colitis. , 1975, Gastroenterology.

[121]  I. Innerfield,et al.  ANTITHROMBIN ACTIVITY IN HOMOCYSTINURIA , 1975, The Lancet.

[122]  D. Jewell,et al.  Azathioprine in Ulcerative Colitis: Final Report on Controlled Therapeutic Trial , 1974, British medical journal.

[123]  D. Jewell,et al.  Intensive intravenous regimen for severe attacks of ulcerative colitis. , 1974, Lancet.

[124]  S. Truelove,et al.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin) , 1973, Gut.

[125]  R. Wright,et al.  Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets , 1966, The American Journal of Digestive Diseases.

[126]  J. H. Baron,et al.  CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITIS , 1965 .

[127]  R. Carpenter,et al.  Controlled trial of sulphasalazine in the treatment of ulcerative colitis , 1964, Gut.

[128]  J. H. Baron,et al.  Variation Between Observers in Describing Mucosal Appearances in Proctocolitis* , 1964, British medical journal.

[129]  J. H. Baron,et al.  Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. , 1962, Lancet.

[130]  Truelove Sc,et al.  Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial. , 1958 .

[131]  S. Truelove,et al.  Treatment of Ulcerative Colitis with Local Hydrocortisone Hemisuccinate Sodium , 1957, British medical journal.

[132]  S. Truelove,et al.  Biopsy Studies in Ulcerative Colitis , 1956, British medical journal.

[133]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .

[134]  M. Vieth,et al.  The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[135]  T. Yao,et al.  Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index , 2002, Journal of Gastroenterology.

[136]  A. Cohen,et al.  Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. , 2001, Gastroenterology.

[137]  Gordon H. Guyatt,et al.  How to Use an Article About Therapy or Prevention , 1995 .

[138]  G. Mantzaris,et al.  Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. , 1994, The American journal of gastroenterology.

[139]  John E. Ware,et al.  SF-36 physical and mental health summary scales : a user's manual , 1994 .

[140]  G. Guyatt,et al.  Users' guides to the medical literature. , 1993, JAMA.

[141]  A. Ekbom.  Ulcerative Colitis and Colorectal Cancer , 1991 .

[142]  Cn Williams.  Efficacy and Tolerance of 5-Aminosalicylic Acid Suppositories in the Treatment of Ulcerative Proctitis: A Review of Two Double-Blind, Placebo Controlled Trials , 1990 .

[143]  J. Lennard-jones,et al.  A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. , 1978, Scandinavian journal of gastroenterology.

[144]  J. Lennard-jones,et al.  A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis. , 1977, Scandinavian journal of gastroenterology.

[145]  O. Bonnevie,et al.  The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year. , 1973, Scandinavian journal of gastroenterology.

[146]  N. Mottet.  Histopathologic spectrum of regional enteritis and ulcerative colitis. , 1971, Major problems in pathology.